ROTH MKM initiated coverage on Stereotaxis with a new price target
$STXS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
ROTH MKM initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $5.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2024 | $5.00 | Buy | ROTH MKM |
| 7/12/2022 | $6.00 | Buy | Aegis Capital |
| 6/23/2022 | $6.00 | Buy | B. Riley Securities |
| 1/5/2022 | $11.00 | Buy | Craig-Hallum |
| 1/5/2022 | $13.00 | Buy | Loop Capital |
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference. David Fischel, Stereotaxis Chairman and CEO, is scheduled to participate in a fireside discussion on Wednesday, December 3rd, 2025, at 9:00 am Eastern Standard Time and will be available that same day for one-on-one meetings. "This is an exciting period for Stereotaxis as we achieve key regulatory milestones and demonstrate early commercial growth," said Mr. Fischel. "We look forward to engaging with investors at the
ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2025. "We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones," said David Fischel, Chairman and CEO. "This is an exciting milestone-rich period in which we are demonstrating the tangible reality and initial commercial impact of our comprehensive innovation strategy." "Our commercial progress includes two Genesis robotic systems ordered by hospitals si
ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received U.S. Food and Drug Administration 510(k) clearance for its latest generation robotic system, GenesisX™. GenesisX is the latest advance in endovascular surgical robotics, building upon the established benefits of Robotic Magnetic Navigation while significantly enhancing the accessibility of the technology for healthcare providers. The system features a compact and efficient design, incorporating magnetic shielding into its structure in place of the shielding otherwise installed in the walls
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
ROTH MKM initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $5.00
Aegis Capital initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00
B. Riley Securities initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00
10-Q - Stereotaxis, Inc. (0001289340) (Filer)
8-K - Stereotaxis, Inc. (0001289340) (Filer)
424B5 - Stereotaxis, Inc. (0001289340) (Filer)
ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine. Stereotaxis CEO, David Fischel, will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Later that day, at 4:45 PM EDT, a distinguished panel of electrophysiologists, including Dr. Daniel Cooper,
ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology. The
ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum "Homi" Shamir to its Board of Directors. Mr. Shamir most recently served as Chairman and Chief Executive Officer of Luminex Corporation from 2014 through its sale to DiaSorin S.p.A. for $1.8 Billion in 2021. Prior to Luminex, Mr. Shamir served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien for $1 Billion in 2014. He currently serves as Chairman of Mediwound, a publicly-traded leader in enzymatic therapeutics for burn and wound-care, and SSI Diagnosti
ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2025. "We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones," said David Fischel, Chairman and CEO. "This is an exciting milestone-rich period in which we are demonstrating the tangible reality and initial commercial impact of our comprehensive innovation strategy." "Our commercial progress includes two Genesis robotic systems ordered by hospitals si
ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 third quarter on Tuesday, November 11, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments. What:Stereotaxis third quarter 2025 financial results conference callWhen:Tuesday, November 11, 2025, at 4:30 p.m. ET (1:30 p.m. PT)Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 646-307-1963 (Internationa
ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. "We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption," said David Fischel, Chairman and CEO. "This is an exciting milestone rich year with broad-based progress across the late stages of our comprehensive innovation strategy." "Recent FDA clearance of MAGiC Sweep was a significant milestone a
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)